AU2005316291A1 - Methods for assessing patients with acute myeloid leukemia - Google Patents

Methods for assessing patients with acute myeloid leukemia Download PDF

Info

Publication number
AU2005316291A1
AU2005316291A1 AU2005316291A AU2005316291A AU2005316291A1 AU 2005316291 A1 AU2005316291 A1 AU 2005316291A1 AU 2005316291 A AU2005316291 A AU 2005316291A AU 2005316291 A AU2005316291 A AU 2005316291A AU 2005316291 A1 AU2005316291 A1 AU 2005316291A1
Authority
AU
Australia
Prior art keywords
protein
gene
aml
expression
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005316291A
Other languages
English (en)
Inventor
Mitch Raponi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Diagnostics LLC
Original Assignee
Janssen Diagnostics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Diagnostics LLC filed Critical Janssen Diagnostics LLC
Publication of AU2005316291A1 publication Critical patent/AU2005316291A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2005316291A 2004-12-17 2005-12-19 Methods for assessing patients with acute myeloid leukemia Abandoned AU2005316291A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US63726504P 2004-12-17 2004-12-17
US60/637,265 2004-12-17
US67011605P 2005-04-11 2005-04-11
US60/670,116 2005-04-11
US74118005P 2005-12-01 2005-12-01
US60/741,180 2005-12-01
PCT/US2005/046100 WO2006066240A2 (fr) 2004-12-17 2005-12-19 Procede d'estimation de patients souffrant d'une leucemie myeloide aigue

Publications (1)

Publication Number Publication Date
AU2005316291A1 true AU2005316291A1 (en) 2006-06-22

Family

ID=36588648

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005316291A Abandoned AU2005316291A1 (en) 2004-12-17 2005-12-19 Methods for assessing patients with acute myeloid leukemia

Country Status (9)

Country Link
EP (1) EP1836313A4 (fr)
JP (1) JP2008523822A (fr)
KR (1) KR20070099564A (fr)
AU (1) AU2005316291A1 (fr)
BR (1) BRPI0515794A (fr)
CA (1) CA2589055A1 (fr)
IL (1) IL183555A0 (fr)
MX (1) MX2007007401A (fr)
WO (1) WO2006066240A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100617467B1 (ko) * 2005-09-27 2006-09-01 디지탈 지노믹스(주) 급성 골수성 백혈병 환자의 항암제 치료 반응성 예측용마커
CN103555825B (zh) * 2007-01-31 2015-09-30 俄亥俄州立大学研究基金会 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物
EP2056110A1 (fr) * 2007-10-31 2009-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Biomarqueur pour prédire une réponse à un traitement par un anti-TNF-alpha
EP2272028A1 (fr) * 2008-04-25 2011-01-12 Koninklijke Philips Electronics N.V. Classification de données d'échantillon
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2012007783A1 (fr) * 2010-07-13 2012-01-19 Institut Gustave Roussy Trousses et procédés de détection de la capacité à induire une mort cellulaire cancéreuse immunogène chez un patient
WO2011131246A1 (fr) * 2010-04-22 2011-10-27 Institut Gustave Roussy Composés et utilisations de ceux-ci pour induire la mort d'une cellule cancéreuse immunogène chez un sujet
EP3556870B9 (fr) 2010-07-27 2022-09-28 Genomic Health, Inc. Procédé d'utilisation de l'expression génique pour déterminer le pronostic du cancer de la prostate
KR101660322B1 (ko) * 2011-04-28 2016-09-29 아크레이 가부시키가이샤 ＮＰＭ1 유전자의 ｅｘｏｎ12 변이의 검출용 프로브 및 그 용도
KR101922761B1 (ko) * 2015-11-18 2018-11-27 가톨릭대학교 산학협력단 급성 골수성 백혈병 진단을 위한 ｃ―Ｋｉｔ 돌연변이 실시간 정량 ＰＣＲ 분석법 및 이의 이용

Also Published As

Publication number Publication date
WO2006066240A3 (fr) 2008-07-17
IL183555A0 (en) 2007-09-20
KR20070099564A (ko) 2007-10-09
WO2006066240A2 (fr) 2006-06-22
JP2008523822A (ja) 2008-07-10
EP1836313A4 (fr) 2010-06-30
MX2007007401A (es) 2007-10-08
CA2589055A1 (fr) 2006-06-22
BRPI0515794A (pt) 2008-08-05
WO2006066240A8 (fr) 2006-09-08
EP1836313A2 (fr) 2007-09-26

Similar Documents

Publication Publication Date Title
US8017321B2 (en) Gefitinib sensitivity-related gene expression and products and methods related thereto
EP3325653B1 (fr) Signature de genes pour thérapies immunitaires pour le cancer
Lamant et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes
AU2005201935B2 (en) Prognostic for hematological malignancy
EP1824997B1 (fr) Alterations genetiques utiles pour predire la response de neoplasies malignes a des traitements medicaux bases sur le taxane
AU2005316291A1 (en) Methods for assessing patients with acute myeloid leukemia
US20160348178A1 (en) Disease-associated genetic variations and methods for obtaining and using same
EP2309273B1 (fr) Détermination de nouveau marqueur de tumeur
US20120245235A1 (en) Classification of cancers
AU2004298604B2 (en) Molecular signature of the PTEN tumor suppressor
US20170275705A1 (en) Biomarkers useful for determining response to pd-1 blockade therapy
US20110166028A1 (en) Methods for predicting treatment response based on the expression profiles of biomarker genes in notch mediated cancers
US20100240057A1 (en) Methods and compositions for the diagnosis and treatment of chronic myeloid leukemia and acute lymphoblastic leukemia
US20180187269A1 (en) Compositions, methods and kits for the diagnosis of carriers of mutations in the brca1 and brca2 genes and early diagnosis of cancerous disorders associated with mutations in brca1 and brca2 genes
CA2662501A1 (fr) Procedes destines a predire une metastase distante du cancer du sein primaire negatif du ganglion lymphatique par analyse de l'expression genique du trajet biologique
US20060240441A1 (en) Gene expression profiles and methods of use
US20110177970A1 (en) Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
CA2608092A1 (fr) Genes de la leucemie et leurs utilisations
US20110143946A1 (en) Method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
US20040191819A1 (en) Expression profiles for breast cancer and methods of use
WO2012022634A1 (fr) Classification, diagnostic et pronostic du myélome multiple
WO2009064481A1 (fr) Identification de nouveaux sous-groupes de patients pédiatriques à haut risque de leucémie lymphoblastique aiguë à précurseurs b, corrélations des issues et procédés diagnostiques et thérapeutiques s'y rapportant
US20110294686A1 (en) Egfr inhibitor therapy responsiveness
US20110301054A1 (en) Method of Stratifying Breast Cancer Patients Based on Gene Expression
WO2014072086A1 (fr) Biomarqueurs pour le pronostic du cancer du poumon

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted